Background/Aims: Colorectal cancer (CRC) is mainly caused by chromosomal instability (CIN) and microsatellite instability (MSI). The RAS and RAF genes are essential components of the CIN pathway, and several studies have found that RAS and RAF mutations are associated with MSI status in CRC. Here, we examined these three factors in CRC in Northeast China and aimed to reveal new details of the relationship between these mutations and MSI status. Methods: This study involved 290 patients with CRC who had RAS or RAF gene mutation detected using fluorescence-based allele-specific polymerase chain reaction or Sanger sequencing. The majority of the identified patients were found to harbor MSI (MSI status). Accurate molecular detection was carried out using formalin-fixed paraffin-embedded tissue or blood samples. Results: The rates of RAS and RAF mutations were 58.5% and 4.1%, respectively. The prevalence of RAS mutation in CRC was clearly higher and that of RAF mutation was lower in Northeast China compared with previously reported cohorts in other locations. High MSI level (MSI-H status) was more complex, at around 10%. This was consistent with previous data from China. However, compared with data reported from other continents, MSI-H was higher than that of Japan or South Korea in Asia, and lower than that of Europe or the United States. 
Comprehensive Analysis of the Relationship Between RAS and RAF Mutations and MSI Status of Colorectal Cancer in Northeastern China
Wenqi Li is to analyze the molecular differences in CRC among different races and compare the latest data from China with previously reported data from various other continents.
Regarding the different parts of the large bowel in the same cohort, although the colon and rectum seem to be a continuous entity, it can be subdivided into three parts: right colon, left colon, and rectum. Each part has different features with different molecular characteristics, clinical manifestations, treatment responses, and outcomes [14] . In order to explore their specific differences and similarities, they may be regarded as three separate parts of the body.
Over time, diagnostic standards and technological innovations may lead to changes in data for the same race. It is also possible that genotypic or phenotypic traits change as a species evolves. For different races, there are few studies on the differences in CRC molecules in different countries so far. Exploring the occurrence and development of CRC in each race, and the changes in CRC molecules in different countries, will help us further understand susceptibility to cancer, vulnerable populations, and adverse factors.
It is extremely difficult to conduct a cross-continent clinical case study due to the high costs and long time required, as well as differences in test standards. However, it is possible to analyze the relationship between the three CRC factors in various countries and regions by extensively reviewing experimental data from various countries.
Materials and Methods

Participants and sample collection
In this study, we investigated 303 patients who had been diagnosed with primary CRC at the Harbin Medical University Cancer Hospital, from January 2016 to November 2017. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissues for PCR analysis or Sanger sequencing. All patients were found to harbor RAS and/or RAF gene mutations (RAS and/or RAF gene status). Based on this, majority of the patients were tested for MSI status. Among these, 290 patients with CRC were eligible, and their DNA was extracted from FFPE tissues for further analysis.
In this study, we collected detailed patient information before performing any analysis. Hence, clinical data of all patients were retrospectively reviewed, including sex, age, lymph node metastasis, pathologic stage, mutational status, and treatment and chemotherapy response, in addition to the treatment course for each patient.
We accumulated cancer cases including 70 cases in the right colon, 80 cases in the left colon, and 140 cases in the rectum for our study. Compared with left-or right-sided colon cancer, a greater proportion of patients had rectal cancer. The position of the tumor, which with the location on the border of the two sides of the colon, was regarded as the major location for the purpose of classification of the final position. All patients underwent radical resection of the primary tumor without preoperative radiotherapy and chemotherapy.
Ethical approval
This study was carried out according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants, and this study was approved by the Institutional Ethics Committee of Harbin Medical University Cancer Hospital (Protocol KY-27).
RAS and RAF detection
Detection of RAS and RAF genes depends mainly on PCR amplification. DNA was extracted from the patient's blood sample or from FFPE tissue using the DNA FFPE Tissue Kit (Applied Biosystems, Foster City, CA). The recommended concentration of DNA template to be used was 1-3 ng/L. The samples were tested using positive and negative controls. The samples were then subjected to PCR with a 7500 Fast Real-Time PCR System (Applied Biosystems). Amplification conditions were as follows: Pre-denaturation at 95°C for 5 min; followed by 15 
MSI detection
MSI status was determined using a 3730 sequencer (Life Technologies, Carlsbad, CA). For this purpose, whole blood samples (1 μL) or prepared FFPE tissue were diluted to 2 ng/μL or 20 ng/μL, respectively, followed by addition of 2.8 μL ddH 2 O, 4 μL 2.5× Buffer A, 2 μL 5× MSI Primer Mix, and 0.2 μL Taq DNA Polymerase I. PCR amplification was carried out as follows: Pre-denaturation at 95°C for 5 min; followed by 30 cycles at 94°C for 30 s, 60°C for 1 min, 70°C for 1 min; and then final extension at 60°C for 30 min. Finally, the temperature was reduced to 15°C, and samples were centrifuged at 3000 rpm for 1 min. NR-21 and BAT-26 were labeled with a blue fluorescent dye, NR-27 and BAT-25 with a green dye, and NR-24 and MONO-27 with a yellow dye. Tumors were termed MSI-H if two or more markers showed instability, MSI-L if only one marker was unstable, and MSS in case of no mutation.
Statistical analysis
All statistical analyses were carried out using the SPSS17.0 software. The independent sample t-test was used to compare the relationship between RAS and RAF mutations and MSI status based on age, site, sex, and other factors. P < 0.05 was considered statistically significant.
Results
Sample selection
In our study, 290 eligible samples were included, (177 male, 113 female). The average age of patients was 59.8 (range 31-87) years. According to the clinical records, there were 80 cases of left colon cancer, 70 cases of right colon cancer, and 140 cases of rectal cancer. We obtained and analyzed the samples over a period of 2 years.
Frequency of RAS mutation RAS status was evaluated in 53 cases using matched normal and tumor FFPE tissue or blood samples ( Fig. 1, 2) . Almost half the patients were male and the remaining were female (26 vs 27) ( Table 1) . RAS mutations are heterozygous, with many kinds of mutations, but are relatively concentrated on specific codons. The majority of the RAS mutations are at KRAS exon 2 (codon 12/13). In our specimens, RAS genes were mutated in 31 cases (58.5%), and 90% (28/31) of these mutations were KRAS mutations. It is worth mentioning that mutations in KRAS exon 2 (codon 12/13) accounted for the vast majority, about 89% (25/28), of all KRAS mutations. The mutation rate of KRAS exon 2 (codon 61) was 1.9% (1/53), the same as that of HRAS exon 2 (codon 12/13) ( Table 2) . Similarly, the mutation rates of KRAS exon 4 (codon 146) and NRAS exon 3 (codon 61) were the same, around 3.8% (2/53). The linear relationship between RAS mutation status and CRC is discontinuous, being highest in the right semicolon, second highest in the rectum, and lowest in the left semicolon. Sex had very little effect on the status of RAS mutation. In our study, the majority of the patients with RAS mutations were less than 50 years of age, suggesting the presence of RAS mutations in patients with early-onset CRC (P = 0.028).
Frequency of RAF mutation
In contrast to RAS mutations, RAF mutations are homozygous. In our study, all RAF mutations were in BRAF V600E ( Fig. 1, 2 ). The RAF gene was detected in 269 patients with CRC, including 166 males and 103 females (Table 1) , and was mutated in 11 patients with a mutation rate of 4.1%. Moreover, analysis based on sex showed a RAF mutation rate of in female patients (5.8%), nearly 2 times higher than that in male patients (3%); there was no statistically significant difference. Next, we aimed to determine the effect of RAF mutations in different locations on CRC. The mutation rates of RAF in the right colon, left semicolon, and rectum were 7.7%, 3.8%, and 2.4%, respectively (Table 2 ). This suggested a linear Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry relationship between RAF mutation and tumor location, a continuous downward trend from the cecum to rectum (Table  1 ). In summary, we can conclude that RAF mutations are closely associated with sex and the proximal colon. In addition, the number of lymph nodes involved was higher in patients with RAF mutations (54.5% vs 12.4%; P = 0.031), and there were more mutations in middle-aged patients than in patients aged less than 60 years (P = 0.020). The risk of poorly differentiated tumors in patients with RAF mutations was significantly increased (P = 0.049).
Well-differentiated tumors were found in patients with BRAF wild-type, but no such case was found in patients with RAF mutant. 
Frequency of MSI status
We determined the MSI status in samples obtained from a total of 240 patients. Results showed that 10% of the patients had MSI-H status and the remaining 90% had MSS status (Table 1) . Interestingly, not even one patient with MSI-L was detected. There was a clear relationship between MSI-H status and tumor location ( Table 2) . MSI-H status in right colon cancer patients was found to be 27.9% (17/61), as shown by a small peak. Compared to this, MSI-H status in left colon and rectal cancer patients was lower: 5.5% (4/73) and 2.8% (3/106), respectively. A descending linear relationship, similar to that of RAF mutation, was observed. The incidence of MSI-H CRC in the right colon was nearly 10 times higher than that in the rectum. Further review of cases showed that patients with MSI-H status were found to have deeper tumor invasion, and MSI-H status was closely associated with poorly differentiated carcinoma or moderately to poorly differentiated carcinoma (P = 0.030). In addition, no case of mutation in lymph node in MSI-H patients was found in our study. There was a significant correlation between MSI status and lymph node metastasis (P < 0.001).
Discussion
RAS is one of the earliest discovered factors that can affect the development of CRC. In this study, the RAS mutation rate was 58.5%. Among the RAS mutations, majority of the mutations were in KRAS exon 2 (codon 12/13), accounting for 47.2%. The rest of the mutations were in the specific RAS gene, which accounted for 19.3% of the total number of mutations. Two mutations each occurred in KRAS exon 2 (codon 164) and NRAS exon 3 (codon 61), while one mutation each occurred in KRAS exon 2 (codon 61) and HRAS exon 2 (codon 12/13). Our data suggested that KRAS is the most important member of the RAS family. Compared with previous research data from China, the total RAS mutation or the specific RAS mutation is higher in this study.
By comparing the mutation rates of KRAS in different countries (Table 3) , the following conclusions were drawn: the KRAS mutation rate among Americans is the highest [15] [16] [17] [18] [19] , followed by Europeans [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , and then Asians [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . KRAS is the most important member of the RAS family. It conforms to the digital relationship of RAS in different countries. NRAS mutation has been the focus of research in recent years. In Asia, the mutation rate seems to be lower than that in other regions [21, 24, 31] , but the difference is not significant. There was no significant difference in NRAS mutation rates in other countries, where the mutation rate was around 2-4%.
In our study, the RAS mutation rate of was significantly higher in cancer located in the proximal colon (85.7%) than in the distal colon cancer (27.2%). In rectal cancer, the rate was 62.8%. The mutation frequency curve was not a straight linear [15, 40] , which is consistent with the results of most of the countries. In addition, some scholars believe 
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that for RAS mutations the frequency curve should be a straight-linear type, descending from the right colon to rectum [25] . On the other hand, most scholars believe that RAS mutations are associated with sex, and the mutation rate in females is significantly higher than that in males [38, 42] , which is different from our findings. RAF, a gene that functions downstream of EGFR, also has some effects on EGFR treatment. RAF mutations are quite common, although the frequency is very low. The RAF mutation rate in the total population is only 4.1%, and is closely associated with right-sided tumors, female sex, and lower age. Hence, it is lower than other cohorts previously reported in China (Table 4) . In Western European countries [33] [34] [35] [36] [37] [38] [39] [40] [43] [44] , most studies demonstrated that the RAF mutation rate was over 10%. In the United States, only a few studies demonstrated a higher mutation rate of RAF [15] [16] [17] 45] . In Asia, the mutation rate is the lowest, ranging between 4-9% [24] [25] [26] [27] [28] [45] [46] [47] .
According to previously obtained data, the mutation rate of RAF decreases from the right colon to rectum, which is in accordance with our data. The frequency of RAF mutation in various countries is 3-8 times higher in colon cancer than in rectal cancer [23, 44] . The ratio of involvement is almost 2-5 times on the right compared to the left [43] . Besides, BRAF has an obvious relationship with tumor position and sex, and is also associated with highgrade tumors, mucous adenocarcinoma, and lymph node metastases.
In our study, MSI-H status was more complex and much higher than current values in China. However, compared with previously reported data from various continents (Table  5) , MSI-H status was higher than that of Japan or South Korea in Asia, and lower than that of Europe or the United States. MSI-H status has a great influence on CRC prognosis. The frequency of MSI-H in the right colon cancer was very high, while that in the left colon and rectum was extremely low (27.9 vs 5.5 vs 2.8, respectively). Previous studies have suggested that MSI-H status in patients with rectal cancer may be associated with hereditary factors, but our study did not come to this conclusion. In addition, MSI-H status is also related to [48] [49] [50] [51] , the frequency of MSI-H status is 10 times higher in colon cancer than in rectal cancer and 2-5 times higher in the right colon than in the left colon. In Europe, MSI-H occurs in about 15-20% of all CRCs [33, 43, 51] . In the United States, it occurs in about 10-15% of all CRCs. In Asia, it occurs in only 5-10% of all CRCs [17, 19] , which is far less than that in other countries [48] [49] [50] .
In our study, there were two distinct mutation samples, in which BRAF mutations occurred in CRCs with MSI-H status, and both were obtained from older female patients with right colon cancer. We also found that the BRAF mutation rate in MSI-H CRC was 2 times higher than that in MSS CRC. However, previous studies have reported that the mutation rate of BRAF in MSI-H tumors is 5, or even 10, times higher than that in MSS tumors.
These two samples were further analyzed. BRAF mutation was associated with younger age and MSI-H status was associated with older age. However, BRAF mutations in MSI-H CRCs occurred in all older patients, and thus we speculate that the role of MSI-H status in CRC is more crucial than that of BRAF mutation. As for the relationship between RAS and RAF, previous studies have not reached the same conclusion. Mainstream research indicates that RAS and RAF are mutually exclusive [52] . However, a few large-scale experiments have shown that the coexistence of RAS and RAF mutations is mostly between 0.5-1.4% [23, 53] .
Finally, there was a unique feature seen in 290 cases of CRC. Among all cases, there were 26 cases of mucinous adenocarcinoma. There were four cases of lymph node metastasis, all of which occurred in the rectum. We speculated that patients with mucinous adenocarcinoma were at a lower risk of metastatic colon cancer.
There are several differences between the data of our current research and that of previous research. These may be attributed to differences in diagnostic criteria, genome evolution, or racial differences.
The molecular status of cancer plays a significant role in the detection of tumors, and differences in the cancer status in each country may be due to various reasons. First, it may be due to race differences, because different genes cause molecular differences in the human body. Second, lifestyle differences, such as eating habits, may also have an impact. Third, it may be caused by environmental factors, such as climate and temperature. The exact reasons still need to be identified by further studies. Exploring the molecular mechanisms that contribute to mutations may help develop strategies for the prevention and treatment of tumors.
Cancer treatment is increasingly relying on tumor markers to predict prognosis and choose a suitable therapeutic plan for patients. Although research in the field of biomarkers is growing, its clinical application is rather limited. A more standardized system of therapeutic markers should be applied in clinical practice, so as to clearly define treatment plans, standardize treatment options, and take full advantage of gene technology.
Conclusion
RAS, RAF, and MSI status all affect the prognosis and treatment of CRC. We found that the frequency of RAS mutation in CRC was obviously higher, while that of RAF mutation was lower than that previously reported in China, and both were lower than the global average. MSI-H status is more complex and is much higher than the current values in China. However, compared with previously reported data from various continents, MSI-H rate was higher than that of Japan or South Korea in Asia, and lower than that of Europe or the United States. These discrepancies may be due to a variety of reasons.
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